Sector News

AstraZeneca seals Aspen Global anesthetics deal

June 9, 2016
Life sciences

Pharmaceutical giant AstraZeneca PLC said Thursday it has reached an agreement with Aspen Pharmacare Holdings Ltd. giving the Johannesburg-listed company rights to its anesthetics portfolio outside the U.S.

Under the deal, Aspen Global Incorporated, a unit of Aspen Pharmacare, will buy commercialization rights outside the U.S. to the portfolio for an upfront payment of $520 million.

Aspen will also pay AstraZeneca up to $250 million in a product sales-related payment, as well as double-digit percentage trademark royalties on product sales.

AstraZeneca said it will manufacture and supply the products on a cost plus basis to Aspen for an initial period of 10 years. Upon completion, Aspen will assume responsibility for all activities relating to the sale of the portfolio in all relevant markets, AstraZeneca added.

The deal isn’t expected to impact AstraZeneca’s financial guidance this year, the company said.

By Ian Walker

Source: MarketWatch

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”